Home/Filings/4/0001225208-25-004942
4//SEC Filing

Ullem Scott B. 4

Accession 0001225208-25-004942

CIK 0001099800other

Filed

May 8, 8:00 PM ET

Accepted

May 9, 7:34 PM ET

Size

17.6 KB

Accession

0001225208-25-004942

Insider Transaction Report

Form 4
Period: 2025-05-07
Transactions
  • Tax Payment

    Common Stock

    2025-05-07$74.92/sh1,406$105,33827,698 total
  • Award

    Common Stock

    2025-05-08+13,40041,098 total
  • Exercise/Conversion

    Common Stock

    2025-05-09$45.28/sh+11,250$509,36352,348 total
  • Award

    Performance Rights

    2025-05-08+13,40013,400 total
    From: 2028-05-08Common Stock (13,400 underlying)
  • Sale

    Common Stock

    2025-05-09$74.40/sh11,250$837,03541,098 total
  • Award

    Employee Stock Option (Right to Acquire)

    2025-05-08+75,20075,200 total
    Exercise: $74.63From: 2026-05-08Exp: 2032-05-07Common Stock (75,200 underlying)
  • Exercise/Conversion

    Employee Stock Option (Right to Acquire)

    2025-05-0911,2500 total
    Exercise: $45.28From: 2019-05-17Exp: 2025-05-16Common Stock (11,250 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    266,318
Footnotes (5)
  • [F1]These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
  • [F2]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2024.
  • [F3]This transaction was executed in multiple trades at prices ranging from $74.12 to $74.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.
  • [F5]Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

Documents

1 file

Issuer

Edwards Lifesciences Corp

CIK 0001099800

Entity typeother

Related Parties

1
  • filerCIK 0001446989

Filing Metadata

Form type
4
Filed
May 8, 8:00 PM ET
Accepted
May 9, 7:34 PM ET
Size
17.6 KB